Skip to main content
Andrea Cerutti

Andrea Cerutti

Institut Hospital del Mar d'Investigacions Mèdiques

Life & Medical Sciences

Andrea Cerutti, MD, PhD, is an ICREA Research Professor since 2010 and leads the B Cell Biology Group at FIMIM, which is a research center located in the PRBB complex. He serves as grant reviewer for the European Research Council and the National Institutes of Health, and as manuscript reviewer for journals such as Cell, Cell Host&Microbe, Science, Nature, Immunity, Nature Immunology, Nature Medicine, Nature Communications, The Journal of Experimental Medicine, Proceedings of the National Academy of Sciences, Cell Reports, etc. He is a member of The American Society for Clinical Investigation, The American Association of Immmunologists, and The Henry Kunkel Society and serves as Associate Editor of Mucosal Immunology. He contributed to the organization of 2014 and 2016 Keystone Symposia meetings, published over 130 research articles in immunology journals, and lectures in international meetings as well as American and European universities.

Research interests

The splenic marginal zone and gut mucosa can be viewed as interfaces between the immune system and the circulation or external environment, respectively. My group studies how B cells strategically positioned in these “frontline” areas make antibodies against circulating or intraluminal antigens, including intestinal microbes. We are particularly interested in the mechanism whereby splenic stromal cells or splenic innate immune cells, including neutrophils, dendritic cells, macrophages and innate lymphoid cells, facilitate the activation of splenic marginal zone B cells. We are also analyzing how intestinal B cells generate antibodies to commensal bacteria and how these antibodies shape the composition of the gut microbiota. Finally, we study the alterations of B cells in patients with primary antibody deficiency, including selective IgA deficiency and common variable deficiency. Our research is relevant to infections, inflammation, autoimmunity, immunodeficiency, and vaccine development.

Selected publications

– de Campos-Mata L, Tejedor Vaquero S, Tachó-Piñot R, Piñero J, Grasset EK, Arrieta Aldea I, Rodrigo Melero N, Carolis C, Horcajada JP, Cerutti A, Villar-García J* & Magri G* 2021, SARS-CoV-2 sculpts the immune system to induce virus-specific naive-like and memory B cell responses‘. Clinical Translational Immunology, vol. 10, no. 9, e1339. *Co-last authors

– Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydillo T, Parigi TL, Ladinsky MS, Ramos I, Dunleavy K, Lee B, Dixon R, Chen ST, Martinez-Delgado G, Nagula S, Bruce EA, Ko HM, Glicksberg BS, Nadkarni G, Pujadas E, Reidy J, Naymagon S, Grinspan A, Ahmad J, Tankelevich M, Bram Y, Gordon R, Sharma K, Houldsworth J, Britton GJ, Chen-Liaw A, Spindler MP, Plitt T, Wang P, Cerutti A, Faith JJ, Colombel JF, Kenigsberg E, Argmann C, Merad M, Gnjatic S, Harpaz N, Danese S, Cordon-Cardo C, Rahman A, Schwartz RE, Kumta NA, Aghemo A, Bjorkman PJ, Petralia F, van Bakel H, Garcia-Sastre A & Mehandru S. 2021, ‘Intestinal host response to SARS-CoV-2 infection and COVID-19 outcomes in patients with gastrointestinal symptoms’. Gastroenterology. 160, 7, 2435 -2450.

– Tejedor Vaquero S, de Campos-Mata L, Ramada JM, Díaz P, Navarro-Barriuso J, Ribas-Llaurado C, Rodrigo Melero N, Carolis C, Cerutti A, Gimeno R* & Magri G 2021,* ‘The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existng immunity’, Frontiers in Immunology, vol. 12, article 737083. doi: 10.3389/fimmu.2021.737083. *Co-last authors

ICREA Memoir 2021